Press Releases

AMSTERDAM & SEATTLE --(BUSINESS WIRE)--Dec. 18, 2019-- myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, today announced a

SEATTLE --(BUSINESS WIRE)--Dec. 16, 2019-- Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology ( ESMO ) 2019 Immuno-Oncology Congress in Geneva, Switzerland .

SEATTLE --(BUSINESS WIRE)--Dec. 13, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting

SEATTLE --(BUSINESS WIRE)--Dec. 10, 2019-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress , which is being held December 11-14, 2019 in

SEATTLE --(BUSINESS WIRE)--Dec. 5, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting

SEATTLE --(BUSINESS WIRE)--Dec. 4, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting

– 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA ; 68 Percent Primary-Endpoint Complete Response Rate for Those Who Received Protocol-Specified Treatment of At Least 4 Weeks of Dosing – – 100-Day

SEATTLE --(BUSINESS WIRE)--Nov. 20, 2019-- Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts .

-- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- SEATTLE --(BUSINESS WIRE)--Nov. 19, 2019-- Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in

Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Nov. 8, 2019-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American

--Prestigious Prize Conferred for GPCR Program Discoveries-- SEATTLE --(BUSINESS WIRE)--Nov. 7, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A.

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019 , on Tuesday, November 12, 2019 , after the market closes.

-- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- SEATTLE --(BUSINESS WIRE)--Nov. 4, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA -approved ophthalmic drug OMIDRIA ®

– Includes Deferral for PIP Completion Until After Approval of Marketing Authorization Application – SEATTLE --(BUSINESS WIRE)--Oct. 29, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion

– Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020 – SEATTLE --(BUSINESS WIRE)--Oct. 28, 2019-- Omeros Corporation (Nasdaq: OMER) has submitted the first sections of the rolling submission of its Biologics License Application (BLA) to the U.S.

  SEATTLE --(BUSINESS WIRE)--Oct. 1, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use during cataract surgery to

  SEATTLE --(BUSINESS WIRE)--Sep. 25, 2019-- Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria ( i.e.

-- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- SEATTLE --(BUSINESS WIRE)--Sep. 16, 2019-- Omeros Corporation (Nasdaq: OMER) today announced positive results from its Phase 1 study with the lead compound in its OMS527 program.

– Omeros Remains On Track to Initiate the Submission Next Quarter – SEATTLE --(BUSINESS WIRE)--Sep. 11, 2019-- Omeros Corporation (Nasdaq: OMER) announced that the United States Food and Drug Administration ( FDA ) agreed with the company’s proposed schedule for the rolling review of the Biologics

-- The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- SEATTLE --(BUSINESS WIRE)--Sep. 10, 2019-- Omeros Corporation (Nasdaq: OMER) today announced a new approach to cancer immunotherapy that targets inhibition of GPR174, a member of the

SEATTLE --(BUSINESS WIRE)--Sep. 6, 2019-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21 st Annual Global Investment Conference in New York next week.

SEATTLE --(BUSINESS WIRE)--Aug. 9, 2019-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday,

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 8, 2019-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Aug. 5, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2019 financial results for the period ended June 30, 2019 , on Thursday, August 8, 2019 , after the market closes.

SEATTLE & BASEL, Switzerland --(BUSINESS WIRE)--Jul. 31, 2019-- Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated

-- Effective October 1, 2019 , New Code Expected to Expand Reimbursement -- SEATTLE --(BUSINESS WIRE)--Jul. 24, 2019-- Omeros Corporation today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare

-- All Criteria for the Response-Based Endpoint Now Finalized -- SEATTLE --(BUSINESS WIRE)--Jul. 11, 2019-- Omeros Corporation today announced agreement with the U.S. Food and Drug Administration ( FDA ) on the response-based primary endpoint for its pivotal trial to support the biologics license

– Preparations Continue for Submission of BLA in the U.S. and MAA in Europe – SEATTLE --(BUSINESS WIRE)--Jun. 5, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA)

SEATTLE --(BUSINESS WIRE)--May 15, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

- Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids- SEATTLE --(BUSINESS WIRE)--May 7, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA -approved ophthalmic drug

SEATTLE --(BUSINESS WIRE)--May 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after the market closes. Omeros management will host a conference call

SEATTLE --(BUSINESS WIRE)--May 1, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA -approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American

-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of

--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and

– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan

SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens.

SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council , in consultation with the World Health Organization’s International Nonproprietary

Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has

-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors.

--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent

– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 .